Non Small Cell Lung CancerNCT06538038
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
An observational study of Non Small Cell Lung Cancer and Epidermal Growth Factor Receptor Gene Mutation, run by PrECOG, LLC. at 146 sites in United States.
Trial summary
The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Growth Factor Receptor (EGFR)-mutant Non-Small Cell Lung Cancer (NSCLC) to better understand the safety and effectiveness… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer
- What is being tested?
- Osimertinib and Osimertinib + Chemotherapy
- Type of treatment
- Pill or oral medicine
- How many people
- 200 participants
- Where
- 146 sitesUnited States
- Study dates
- 17 Sep 2024to Aug 2029
- How long will I take part?
- 3 Years
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with EGFR-mutated NSCLC, not being treated in a clinical trial but receiving osimertinib +/- chemotherapy at academic and community practices participating in PrE1702 registry.
Who may be able to join
- Patient must have a pathologically-confirmed diagnosis of non-small cell lung cancer (NSCLC).
- Patient must have advanced disease, defined as IIIB (not amenable to definitive multi-modality therapy), IIIC, or IV (includes local or distant recurrent disease after a prior diagnosis of Stage I-III disease). All staging is via the American Joint Committee on Cancer (AJCC)/International Association for the Study of Lung Cancer (IASLC) 8th edition staging criteria.
- Patient tumor must have somatic activating sensitizing mutation in EGFR (e.g., but not limited to Exon 19 deletion, L858R, E709X, G719X, exon 19 insertions, L861Q, S768I). Patients with non-sensitizing mutations in EGFR (EGFR exon 20 insertions) are not eligible. Plasma, cytology, or tumor tissue can be utilized for standard of care mutation testing.
- Prior chemotherapy and/or immunotherapy administered as primary treatment for NSCLC before EGFR mutation was identified is allowed ≤ 45 days of study registration to allow for return of sequencing information.
- Prior treatment with osimertinib administered as primary treatment for NSCLC is allowed ≤ 30 days of study registration (prior treatment with any other EGFR TKI agent is not allowed).
- Patient must not be participating in EA5182 or any other cancer treatment trial. Osimertinib or osimertinib + chemotherapy/immunotherapy given as first-line treatment for this disease cannot be given as part of a clinical trial.
- Patients that have received prior radiation therapy in any setting for this disease are eligible.
- Adults age ≥ 18 years.
Who cannot join
None listed.
Trial locations and contacts
146 sites in 1 country.
146 sites in 1 country
United States146 sites
ThedaCare Regional Cancer Center
Appleton, Wisconsin, 54911
ThedaCare Regional Medical Center - Appleton
Appleton, Wisconsin, 54911
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, 21201
Greater Baltimore Medical Center
Baltimore, Maryland, 21204
Advocate Good Shepherd Hospital
Barrington, Illinois, 60010
ThedaCare Cancer Care - Berlin
Berlin, Wisconsin, 54923
University of Alabama at Birmingham
Birmingham, Alabama, 35294
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler: SJC Bluffton Campus
Bluffton, South Carolina, 29910
Tufts Medical Center
Boston, Massachusetts, 02111
Aurora Cancer Care-Southern Lakes VLCC
Burlington, Wisconsin, 53105
Minnesota Oncology - Burnsville
Burnsville, Minnesota, 55337
Cambridge Medical Center
Cambridge, Minnesota, 55008
Aultman
Canton, Ohio, 44710
Miami Valley Hospital South
Centerville, Ohio, 45459
Northwestern University
Chicago, Illinois, 60611
John H Stroger Jr Hospital of Cook County
Chicago, Illinois, 60612
Advocate Illinois Masonic Medical Center
Chicago, Illinois, 60657
Baptist Memorial Hospital and Cancer Center - Collierville
Collierville, Tennessee, 38017
Baptist Memorial Hospital and Cancer Center - Golden Triangle
Columbus, Mississippi, 39705
Mercy Hospital
Coon Rapids, Minnesota, 55433
Aurora Saint Luke's South Shore
Cudahy, Wisconsin, 53110
UT Southwest
Dallas, Texas, 75235
Geisinger Medical Center
Danville, Pennsylvania, 17822
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois, 60115
Bayhealth
Dover, Delaware, 19901
The Cancer Institute at St. Francis Hospital
East Hills, New York, 11548
Fairview Southdale Hospital
Edina, Minnesota, 55435
Stanford Cancer Center Emeryville
Emeryville, California, 94608
Miami Valley Hospital North
Englewood, Ohio, 45415
Mercy Clinic Fort Smith Communities
Fort Smith, Arkansas, 72903
Mercy Research
Fort Smith, Arkansas, 72903
JPS Oncology & Infusion Center
Fort Worth, Texas, 76104
Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio, 45005
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois, 60134
AHC Germantown Health Center
Germantown, Wisconsin, 53022
Northwestern Medicine Glenview Outpatient Center
Glenview, Illinois, 60026
Aurora Cancer Care-Grafton
Grafton, Wisconsin, 53024
Northwestern Medicine Grayslake Outpatient Center
Grayslake, Illinois, 60030
Aurora BayCare Medical Center
Green Bay, Wisconsin, 54311
Miami Valley Cancer Care and Infusion
Greenville, Ohio, 45331
Baptist Cancer Center - Grenada
Grenada, Mississippi, 38901
Advocate South Suburban Hospital
Hazel Crest, Illinois, 60429
Geisinger Medical Center-Cancer Center Hazleton
Hazleton, Pennsylvania, 18201
UNC Pardee Cancer Center
Hendersonville, North Carolina, 28791
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler: South Carolina Cancer Specialists
Hilton Head Island, South Carolina, 29926
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler: Liberty County Cancer Care
Hinesville, Georgia, 31313
Jackson Oncology Associates PLLC
Jackson, Mississippi, 39202
Mississippi Baptist Medical Center
Jackson, Mississippi, 39202
Mercyhealth Hospital and Cancer Center - Janesville
Janesville, Wisconsin, 53548
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler: Regional Cancer Care
Jesup, Georgia, 31545
Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas, 72401
Mercy Clinic Joplin, LLC
Joplin, Missouri, 64804
Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin, 53142
Gundersen Lutheran Medical Foundation
La Crosse, Wisconsin, 54601
Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois, 60045
Geisinger Medical Oncology-Lewisburg
Lewisburg, Pennsylvania, 17837
Lewistown Hospital
Lewistown, Pennsylvania, 17044
Lowell General Hosptial
Lowell, Massachusetts, 01854
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53715
Fairview Clinics and Surgery Center Maple Grove
Maple Grove, Minnesota, 55369
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Marshfield Medical Center
Marshfield, Wisconsin, 54449
Baptist Memorial Hospital and Cancer Center - Memphis
Memphis, Tennessee, 38120
Baptist Memorial Hospital for Women
Memphis, Tennessee, 38120
Satellite of Bayhealth Sussex
Milford, Delaware, 19901
Aurora Cancer Care-Milwaukee
Milwaukee, Wisconsin, 53209
Aurora NCORP
Milwaukee, Wisconsin, 53215
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, 53215
Aurora West Allis Medical Center
Milwaukee, Wisconsin, 53227
Aurora Sinai Medical Center
Milwaukee, Wisconsin, 53233
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Health Partners Inc.
Minneapolis, Minnesota, 55454
Monticello Cancer Center
Monticello, Minnesota, 55362
Virtua Samson Cancer Center
Moorestown, New Jersey, 08057
Atlantic Health Cancer Consortium Community Oncology Research Program
Morristown, New Jersey, 07960
Morristown Medical Center
Morristown, New Jersey, 07960
Vanderbilt University
Nashville, Tennessee, 37232
ThedaCare Regional Medical Center - Neenah
Neenah, Wisconsin, 54956
Baptist Memorial Hospital and Cancer Center - Union
New Albany, Mississippi, 38652
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903
ThedaCare Cancer Care - New London
New London, Wisconsin, 54961
New Ulm Medical Center
New Ulm, Minnesota, 56073
Montefiore
New York, New York, 10467
Carle Cancer Institute Normal
Normal, Illinois, 61761
Advocate Christ Medical Center
Oak Lawn, Illinois, 60453
Mercy Clinic Oklahoma Communities, Inc.
Oklahoma City, Oklahoma, 73120
Northwestern Medicine Orland Park
Orland Park, Illinois, 60462
ThedaCare Cancer Care - Oshkosh
Oshkosh, Wisconsin, 54904
Vince Lombardi Cancer Clinic-Oshkosh
Oshkosh, Wisconsin, 54904
Baptist Memorial Hospital and Cancer Center - Oxford
Oxford, Mississippi, 38655
Stanford Cancer Institute Palo Alto
Palo Alto, California, 94304
Lankenau Medical Center
Paoli, Pennsylvania, 19301
The Valley Hospital - Luckow Pavilion
Paramus, New Jersey, 07652
Advocate Lutheran General Hospital
Park Ridge, Illinois, 60068
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107
Jefferson Torresdale Hospital
Philadelphia, Pennsylvania, 19114
Einstein Medical Center
Philadelphia, Pennsylvania, 19141
FirstHealth of the Carolinas-Moore Regional Hospital
Pinehurst, North Carolina, 28374
Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212
Geisinger Cancer Services-Pottsville
Pottsville, Pennsylvania, 17901
Fairview Northland Medical Center
Princeton, Minnesota, 55371
Aurora Cancer Care-Racine
Racine, Wisconsin, 53406
North Memorial Medical Health Center
Robbinsdale, Minnesota, 55422
Mercy Clinic Cancer and Hematology
Rolla, Missouri, 65401
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, 55416
Metro MN
Saint Louis Park, Minnesota, 55426
Regions Hospital
Saint Paul, Minnesota, 55101
United Hospital
Saint Paul, Minnesota, 55102
Stanford Cancer Center South Bay
San Jose, California, 95124
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah, Georgia, 31405
Community Medical Center
Scranton, Pennsylvania, 18510
Sidney Kimmel Cancer Center Washington Township
Sewell, New Jersey, 08080
Saint Francis Regional Medical Center
Shakopee, Minnesota, 55379
ThedaCare Cancer Care - Shawano
Shawano, Wisconsin, 54166
Vince Lombardi Cancer Clinic-Sheboygan
Sheboygan, Wisconsin, 53081
Baptist Memorial Hospital and Cancer Center - Desoto
Southhaven, Mississippi, 38671
Mercy Clinic Springfield Communities
Springfield, Missouri, 65804
Mercy Clinic East Communities
St Louis, Missouri, 63128
Mercy Clinic East Communities
St Louis, Missouri, 63141
Geisinger Medical Group
State College, Pennsylvania, 16801
Lakeview Hospital
Stillwater, Minnesota, 55082
Tufts Medical Center Cancer Center Stoneham
Stoneham, Massachusetts, 02180
Overlook Medical Center
Summit, New Jersey, 07901
Aurora Medical Center in Summit
Summit, Wisconsin, 53066
SUNY Upstate Medical University
Syracuse, New York, 13210
Montefiore Medical Center-Einstein Campus
The Bronx, New York, 10461
Upper Valley Medical Center
Troy, Ohio, 45373
Vince Lombardi Cancer Clinic-Two Rivers
Two Rivers, Wisconsin, 54241
Carle Founation Hospital
Urbana, Illinois, 61801
Virtua Voorhees
Voorhees Township, New Jersey, 08043
Ridgeview Medical Center
Waconia, Minnesota, 55387
John Muir Health
Walnut Creek, California, 94598
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois, 60555
Sibley Johns Hopkins University
Washington D.C., District of Columbia, 20016
ProHealth
Waukesha, Wisconsin, 53022
ThedaCare Cancer Care - Waupaca
Waupaca, Wisconsin, 54981
Aurora Cancer Care-Milwaukee West
Wauwatosa, Wisconsin, 53226
Good Samaritan University Hospital
West Islip, New York, 11795
Geisinger Wyoming Valley/Henry Cancer Center
Wilkes-Barre, Pennsylvania, 18711
Rice Memorial Hospital
Willmar, Minnesota, 56201
Asplundh Cancer Pavilion
Willow Grove, Pennsylvania, 19090
Minnesota Oncology Hematology PA-Woodbury
Woodbury, Minnesota, 55125
Fairview Lakes Medical Center
Wyoming, Minnesota, 55092
About this study
Official title: Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/- Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients
The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Growth Factor Receptor (EGFR)-mutant Non-Small Cell Lung Cancer (NSCLC) to better understand the safety and effectiveness of these standard of care regimens.
Read the detailed description
This study tests the feasibility of using real-world data collection through the recruitment of well-characterized patients into a registry, spanning academic and community practice sites to determine patient outcomes in all-comers. The scientific community would further benefit from a greater understanding of the safety and effectiveness of newly approved therapies prescribed in routine clinical practice.
Non-interventional (observational) study with 250 participants per exposure group (maximum accrual up to 538 total participants) comparing outcomes in patients with EGFR-mutated NSCLC, not being treated in a clinical trial but receiving standard of care osimertinib +/- chemotherapy.
The treating physician determines whether a patient will receive standard of care single agent osimertinib or osimertinib with chemotherapy and the planned treatment is recorded at registration.
Clinical/Imaging assessments will be per the treating physician.
- Conditions
- Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer, Stage IV Lung Cancer
- Being tested
- Osimertinib, Osimertinib + Chemotherapy
- Keywords
- Osimertinib, Cisplatin, Carboplatin, Pemetrexed, EGFR Mutated
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OsimertinibDrug
Also called Tagrisso
Single agent Osimertinib by mouth once daily. Dosing and administration of osimertinib will be administered as per routine standard of care per the package insert or per institutional guidelines.
Osimertinib + ChemotherapyDrug
Also called Tagrisso, Cisplatin, Carboplatin, Pemetrexed
Osimertinib by mouth once daily + Chemotherapy. Chemotherapy choice will be per treating physician. Dosing and administration of osimertinib +/- chemotherapy agents will be administered as per routine standard of care per the package insert or per institutional guidelines.
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Osimertinib Receives: Drug: Osimertinib | |
| Group 2 | Osimertinib + Chemotherapy Receives: Drug: Osimertinib + Chemotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
real-world Progression-Free Survival (rwPFS)
Time from initiating therapy to progression or death without documented progression
Measured: From initiation of therapy to progression or death, up to 3 years
Secondary outcomes (2)
real-world Overall Survival (rwOS)
Time from initial therapy to death from any cause.
Measured: From initiation of therapy to death, up to 3 years
real-world time to treatment discontinuation (rwTTD)
Time from treatment initiation (osimertinib or osimertinib + chemotherapy) to discontinuation of osimertinib.
Measured: From initiation of therapy to discontinuation of osimertinib, up to 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2024
- Study start17 Sep 2024
- Primary completionAug 2028 (estimated)
- Study completionAug 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non Small Cell Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (actual)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- PrECOG, LLC.
- Sponsor type
- University, hospital or other
- Collaborators
- ECOG-ACRIN Cancer Research Group
- Responsible party
- Sponsor
- Investigators
- Suzanne Cole, MD, Study chair, UT Southwestern Simmons Comprehensive Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06538038
- Sponsor's protocol ID
- PrE1702
- Status last verified
- Sep 2026
- First submitted
- 31 Jul 2024
- Last updated
- 9 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: Data is proprietary.